Reuters citing the European Medicines Agency on the 11th local time that the European Medicines Agency is currently investigating three new side effects that may be caused by the Pfizer and Moderna's new crown vaccine, namely polymorphic erythema (an acute and inflammatory skin disease), glomerulonephritis and nephrotic syndrome .
The European Medicines Agency has now asked Pfizer and Moderna to provide more data to analyze the possible connections between vaccination and the above conditions. However, the European Medicines Agency has not disclosed the specific number of cases of the above symptoms after receiving the related vaccine.
The European Medicines Agency stated in early July that there is a connection between cardiac inflammation and vaccination with Pfizer and Moderna's new crown vaccines. After receiving the Pfizer and Moderna COVID-19 vaccines, myocarditis and pericarditis may occur in very rare cases. The committee recommended adding two symptoms of myocarditis and pericarditis to the side effects information of vaccine products, and warned and informed medical staff and those preparing to receive the relevant vaccine.
Look at modernna, BioNTech stock
[ US stock vaccine stocks fell, the European Medicines Agency launched an investigation into more potential side effects of mRNA vaccines] August 12 | According to foreign media, the European Medicines Agency said on Wednesday that it is investigating many adverse reactions reported after vaccination, involving erythema polymorphism, nephritis and nephrotic syndrome. The agency asked Pfizer/BioNTech and Moderna to provide more data. According to statistics, as of July 29, a total of 330 million doses of Pfizer vaccine have been received in Europe, and the number of people vaccinated with Moderna vaccine was about 43.5 million. Affected by this news and earlier concerns about the excessive valuation of in related stock, Moderna fell 15.64% on Wednesday, with a cumulative decline of more than 20% in the past two days, Pfizer fell 3.9%, and BioNTech fell 13.76%
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-